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Abstract
Background: Catheter-associated urinary tract infection (CAUTI) is a common nosocomial device-associated
infection. It is now recognized that the high infection rates were caused by the formation of biofilm on the surface
of the catheters that decreases the susceptibility to antibiotics and results in anti-microbial resistance.
In this study, we performed an in vitro test to explore the mechanism of biofilm formation and subsequently
conducted a multi-center clinical trial to investigate the efficacy of CAUTI prevention with the application of JUC, a
nanotechnology antimicrobial spray.
Methods: Siliconized latex urinary catheters were cut into fragments and sterilized by autoclaving. The sterilized
sample fragments were randomly divided into the therapy and control group, whereby they were sprayed with
JUC and distilled water respectively and dried before use.
The experimental standard strains of Escherichia coli (E. coli) were isolated from the urine samples of patients. At 16
hours and 7 days of incubation, the samples were extracted for confocal laser scanning microscopy.
A total of 1,150 patients were accrued in the clinical study. Patients were randomized according to the order of
surgical treatment. The odd array of patients was assigned as the therapy group (JUC), and the even array of
patients was assigned as the control group (normal saline).
Results: After 16 hours of culture, bacterial biofilm formed on the surface of sample fragments from the control
group. In the therapy group, no bacterial biofilm formation was observed on the sample fragments. No significant
increase in bacterial colony count was observed in the therapy group after 7 days of incubation.
On the 7th day of catheterization, urine samples were collected for bacterial culture before extubation. Significant
difference was observed in the incidence of bacteriuria between the therapy group and control group (4.52% vs.
13.04%, p < 0.001).
Conclusions: In this study, the effectiveness of JUC in preventing CAUTI in a hospital setting was demonstrated in
both in vitro and clinical studies.
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Background
Catheter-associated urinary tract infection (CAUTI) is a
common nosocomial device-associated infection. Urinary
tract infection (UTI) accounts for up to 40% of nosoco-
mial infections and is one of the main types of health-
care-associated infections (HAI). About 80% of UTIs are
catheter-associated [1,2]. In the United States, approxi-
mately 95% of UTIs were associated with the indwelling
catheters [3], and interestingly, 15-25% of patients in
short-term hospital care need to be inserted with indwel-
ling urinary catheters [4]. Every year, there are more than
5 million patients necessitating catheterization therapy
[5] and approximately 1 million patients suffering from
CAUTI [6]. The findings of a European study indicated
that 5.4% of patients aged 65 or above required the use of
an indwelling urinary catheter [7].
CAUTI is a highly common infection and comes with
considerable risk. The duration of hospitalization owing to
CAUTI increased from 2.4 to 5.4 days in the United States
[8]. On average, the costs of diagnosing and treating
CAUTI is US$ 589, excluding extension of hospital costs
[9]. Taking into account the expenses of hospitalization,
the average cost increases from US$ 2,836 to 3,803
[10,11]. The Centers for Disease Control and Prevention
(CDC) pointed out that UTI leads to deaths of over 13,000
patients every year in the United States [12], indicating a
growing medical problem.
It is now recognized that the high infection rates were
caused by the formation of biofilm on the surface of the
catheters that decreases the susceptibility to antibiotics
and results in anti-microbial resistance [8,13,14]. The for-
mation of biofilm as a result of extracellular polysacchar-
ide matrix secretions from microorganisms has been
demonstrated in clinical studies. Bacterial biofilm is a spe-
cial honeycomb-shaped structure that forms a very com-
plex ecosystem; magnification of biofilm will reveal
microcolonies under the microscope [15-18]. Organisms
with biofilm can withstand shear force, pH changes, and
antimicrobial agents, and prevent macrophage phagocyto-
sis [13,19]. The proximity of cells allows more frequent
genetic information exchange than other free cells [20].
Therefore, antimicrobial resistance genes and strains can
be spread easily. With respect to catheters, the formation
of biofilm will protect the pathogenic bacteria residing at
the urinary tract from antimicrobial medicine and host
immune response [15]. It will then facilitate the growth of
bacteria which further complicates the problem of CAUTI
[13].
Recent research focused on the development of preven-
tive methods for biofilm formation and changes, includ-
ing furanone, furacilinum, silver-coated catheters, in
addition to other techniques. [21-24]. Johnson et al.
[21,2] discovered that catheters containing silver hydrogel
and nitrofurazone coating have excellent effects of
inhibiting biofilm formation, but no inhibitory effects for
Pseudomonas aeruginosa. According to the study con-
ducted by CDC, the results of a comparison of patients
inserted with silver-coated catheters and standard cathe-
ters for one week revealed no difference in bacteriuria
prevention [25]. Silver-bearing catheters can decrease the
effect of bacteriuria in a week after indwelling. Burton
et al.[8] discovered the new oPDM-plus-PS (N, N’-(1,2-
phenylene) dimaleimide [oPDM]-plus-protamine sulfate
[PS]) coating can inhibit Pseudomonas aeruginosa and
Staphylococcus epidermidis adhering to the catheters, but
now these coated catheters can only provide short-term
CAUTI prevention upon urinary catheter insertion [13].
Recently, Stickler et al.[26] revealed that bacteria on the
biofilm of catheters produced quorum-sensing signal that
can control the genetic expression of forming biofilm. If
the signal is blocked, the formation of biofilm can be
impeded. For example, the mutant Pseudomonas aerugi-
nosa in the absence of quorum-sensing signal was unable
to produce a three-dimensional biofilm [27]. An impor-
tant finding was established regarding iron and the for-
mation of biofilm. Clinical investigations have detected
that elements such as iron are necessary nutrients for
biofilm formation. The production of catheters without
iron is a new development, but it has not been tested in
clinical trials [13]. The use of probiotics can also be con-
sidered. Trautner et al.[28,29] observed that the rates of
pathogenic bacterial infection and CAUTI were reduced
if the catheters were inoculated with the non-pathogenic
Escherichia coli (E. coli). Although these methods are
considerable, there is no conclusive evidence and the
cost-effectiveness remains unclear.
The traditional use of JUC applied to the wounds of
post-surgery patients has proven to be effective in the hos-
pital and out-patient setting: application of JUC did not
result in drug resistance, nor stimulate serious adverse
reactions and reduced the average wound healing time of
patients [30]. JUC is composed by nano-manufacture tech-
nology, with nano-cations on the nano-scale molecular
structure produced and then prepared in water-soluble
spray [31]. JUC achieves antibacterial action on skin and
wound surface by physical mechanisms and can therefore
be regarded as a physical antimicrobial agent [31]. Upon
application, JUC prevents bacterial growth by forming an
invisible, positively charged protective film on the sprayed
surface, isolating and eradicating negatively charged patho-
genic micro-organisms including bacteria, fungi and
viruses [31,32].
There is no effective way to prohibit biofilm formation
clinically; therefore, there is still an unmet need for the
establishment of a new clinical application. In this study,
we performed an in vitro test to explore the mechanism
of biofilm formation and subsequently conducted a mul-
ticenter clinical trial to investigate the efficacy of CAUTI
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The experimental standard strains of E. coli were iso-
lated from the urine samples of UTI patients at the
Second Hospital of Lanzhou University. Bacteria were
cultured in Luria-Bertaini broth [33]. The bacterial sus-
pension was prepared and the bacterial concentration
was adjusted to 7.4 × 109CFU/ml.
Preparation of sample fragment
Siliconized latex urinary catheters were cut into sample
fragments and sterilized by autoclaving. The sterilized
sample fragments were randomly divided between the
therapy and control group, with 8 pieces of fragments in
each group. The sample fragments were respectively
sprayed with JUC and distilled water, and dried before use.
The E. coli suspension was injected into 24 well plates in
which the sample fragments were placed. The plates were
then incubated at 37 °C and washed with PBS solution
every 48 hours [34]. At 16 hours and 7 days of incubation,
the samples were extracted for confocal laser scanning
microscopy.
Confocal laser scanning microscopy
The cultured samples were soaked in 1 ml PBS solution.
After 50 μg/ml propidium iodide was added, the sam-
ples were left for dyeing in a dark area at 4°C for
15 minutes or at room temperature for 30 minutes. The
samples were then placed upside down on a glass slide
for observing the biofilm formation using laser scanning
microscopy [35,36].
Clinical trial
The clinical study commenced in March 2010 and was
completed in December 2011. Patients undergoing urolo-
gical surgery in need of indwelling urethral catheter and
more than 7 days of hospitalization were recruited. A
total of 1,150 patients (869 male and 281 female), aged
from 2 to 82 years, were accrued. Twenty-three hospitals
participated in this clinical trial, and every hospital
accrued 25 patients each to the control group and ther-
apy group. All patients were operated due to urological
diseases, including but not limited to urinary tract stones,
tumors, prostatic hyperplasia, ureteral stenosis and
hydronephrosis. Indwelling urethral catheter was neces-
sary for patients requiring over 7 days of hospital stay.
The midstream urine bacterial culture [15-17] was nega-
tive at the time of inclusion in the study. Exclusion cri-
teria of the study included patients with a long-term use
of balloon catheter, intermittent self-catheterization, pre-
vious treatment of percutaneous paracentetic suprapubic
cyctostomy and UTI patients. Patients were randomized
according to the order of surgical treatment. The odd
array of patients (575 cases) was assigned as the therapy
group (the JUC), and the even array of patients (575
cases) was assigned as the control group (normal saline).
Patients who were eligible for the trial were explained the
nature and purpose of the trial by the investigator, and
informed consent was obtained for inclusion in the trial.
The Ethics Committee of Tongji Hospital approved the
clinical study (Approval Number: 2010006D).
Study design
Therapy group
Prior to the insertion of the catheter into the ureter of the
patient at the time of surgery, JUC was sprayed on the sur-
face of the catheter to allow formation of a physical anti-
microbial membrane. After surgery, in addition to tradi-
tional nursing care, JUC was sprayed onto the skin and
mucous membrane around the urethral orifice, the cathe-
ter and the drainage tube attachment point. This was done
twice a day with 1 ml per spray (approximately 10 sprays)
until the catheter was removed on the 7th day.
Control group
The catheter was inserted during surgery. After surgery,
conventional nursing care with normal saline was per-
formed until the catheter was removed on the 7th day.
During the study, and according to routine clinical
practice, antibiotics were prescribed to patients after
surgery. The types, dosage and route of antibiotics pre-
scribed to the patients were carefully and strictly
recorded according to the class of antibiotics per institu-
tional guidelines (Table 1).
Class one, class two and class three antibiotics were
cumulatively given 521 (40.08%), 572 (44%) and 207
(15.92%) treatment times respectively. There were no
restrictions of use for class one antibiotics: they were pro-
ven to be safe and effective for long-term clinical applica-
tion with minimal effects on antimicrobial resistance.
The drugs belonging to class one are considered rela-
tively inexpensive antimicrobial agents. Class two anti-
biotics demonstrated properties of restricted use, with
concerned safety, efficacy, and antimicrobial resistance in
humans. In comparison, class two drugs were relatively
more expensive than the drugs of class one, non-
restricted use antibiotics. Class three antibiotics are
newly approved, antimicrobial agents with limited safety
and efficacy information. There were reported adverse
reactions with the use of class three antibiotics. Owing to
the concerned safety of class three drugs, they are not
recommended for use. Special attention should be made
for clinical use to avoid bacterial resistance to antimicro-
bial agents. Amongst the three classes of antibiotics, class
three are relatively more expensive in nature.
The clinical practice on the use of antibiotics differed
between all hospitals. A total of 150 patients required the
combination use of antibiotics, which were prescribed for
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0 to 7 days according to the condition of the patient. The
percentage use of class one antibiotics in Guangzhou
First Municipal People’s Hospital and The First Affiliated
Hospital of the Sun Yat-sen University was 97.92% and
94.12% respectively, but the use of class two antibiotics
was 97.40% in Daping Hospital of the Third Military
Medical University. No significant difference was
observed in the use of antibiotics between therapy and
control groups in each hospital. For example, in the
Second Hospital of Xi’an Jiaotong University, class one
antibiotics were given to 10 cases in both therapy and
control groups, class two antibiotics were given to 12 and
18 cases in treatment and control groups respectively,
and class three antibiotics were given to 8 and 6 cases in
treatment and control groups respectively. In the General
Hospital of Guangzhou Military Command of PLA, class
one antibiotics were given to 10 cases in both the therapy
and control groups, class two antibiotics were given to 13
and 16 cases in the treatment and control groups respec-
tively, and class three antibiotics were given to 4 and 3
cases in treatment and control groups respectively.
Despite the difference in the clinical practice on the use
of antibiotics between hospitals, the results were statisti-
cally meaningful.
After surgery, the body temperature and UTI symptoms
were recorded every day. After 7 days of catheterization,
urine samples were collected under aseptic condition for
bacterial culture before extubation [37].
Outcome assessment
The collected urine samples with colony count ≥ 103
CFU/ml was considered as CAUTI, based on the quanti-
tative urine culture. [9,38,39].
Statistical analysis
Parameters were compared using SPSS version 14.0. The
T-test was used to compare the incidence of CAUTI
between groups, where P < 0.05 was considered as sta-
tistically significant.
Results
In vitro test results
After 16 hours of culture, bacterial biofilm formed on
the surface of sample fragment in the control group.
The bacterial biofilm was dyed red by propidium iodide
fluorescent dye (Figure 1A). In the therapy group, no
bacterial biofilm formation was observed on the sample
fragments. Only small red dots representing a very small
number of free bacteria were observed under micro-
scope (Figure 1B).
After 7 days of culture, in the control group with dis-
tilled water, the surface of the sample fragments formed
a thick, uniform color, dense and darkly stained layer of
bacterial biofilm. Due to bacterial overgrowth, the bio-
film was cross-linked to form clumps of bacteria and
the surface of the sample fragments was rough and
uneven (Figure 2A). The surface of sample fragments in
the therapy group formed only a small amount of thin
membranous structure with smooth surface and light
color. No other abnormality was observed (Figure 2B).
Clinical trial results
Significant difference was not observed in demographics
including age, gender, etiology, and geographical distri-
bution between the two groups. On the 7th day of cathe-
terization, urine samples were collected for bacterial
culture before extubation. In the therapy group, positive
bacterial culture was detected in 26 (4.52%) cases, of
which 24 cases were E. coli, 1 case was Enterococcus fae-
calis and 1 case was smooth Candida. In the control
group, bacteriuria was detected in 75 (13.04%) cases, of
which 69 cases were E. coli, 2 cases were Enterococcus
faecalis, 2 cases were Enterococcus cloacae, 1 case was
Candida albicans and 1 case was Pseudomonas aerugi-
nosa. Detailed results were shown in Table 2. Among all
101 cases of infections, 93 (92.08%) cases were E. coli
infections, 3 (2.97%) cases were Enterococcus faecalis,
and 2 (1.98%) cases were Enterococcus cloacae. Signifi-
cant difference was observed in the incidence of
Table 1 Classification of antibiotics used in the clinical trial




1 piperacillin, nafcillin, mezlocillin, azlocillin, ticarcillin, mezlocillin, amoxicillin, cefazolin, ceftazidime,
cefathiamidine, cefprozil, cefixime, cefotiam, ceftriaxone, cefaclor, Cefonicid sodium, cefamandole sulfate,
azithromycin, levofloxacin, ciprofloxacin,Lomefloxacin, enoxacin, gatifloxacin, amikacin, Amikacin’
Thiamphenicol, clindamycin
27 521 40.08%
2 ampicillin / sulbactam sodium, timentin / clavulanate, mezlocillin / sulbactam, amoxicillin / clavulanic acid,
amoxicillin / sulbactam sodium, piperacillin / sulbactam sodium, cefuroxime sodium, cefmenoxime,
cefotaxime sodium,cefpiramide, cefminox, cefodizime, cefpodoxime proxetil, cefetamet pivoxil, cefdinir,
aztreonam, latamoxef sodium, cefoxitin sodium, sparfloxacin, moxifloxacin, fleroxacin, antofloxacin
hydrochloride, tosufloxacin, etimicin, sisomicin, fusidate sodium, ornidazole
27 572 44%
3 Ceftizoxime, ceftazidime, ceftazidime, cefoperazone, cefoperazone / sulbactam sodium, ceftriaxone /
sulbactam sodium, ceftriaxone / sulbactam sodium, cefoperazone / tazobatan, cefepime, cefoselis,
imipenem / cilastatin, meropenem, Norvancomycin
13 207 15.92%
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bacteriuria between the control group and control group
(4.52% vs. 13.04%, p < 0.001).
Discussion
Types of bacteria
UTI is a major nosocomial infection. CAUTI is one of
the most common types of bacterial infections [1,2];
ample intestinal bacteria cultivates around the urethra
[3,38]. A majority of the short-term CAUTIs were
caused by a single strain of bacteria, such as E. coli, Pro-
teus mirabilis and Klebsiella pneumoniae, whereas long-
term CAUTI was caused by multiple microorganisms
[3,40,41]. Urethra pathogenic E. coli is the most com-
mon cause of CAUTI which constitutes 50% of hospital-
acquired UTIs [3,42]. In our study, similar results were
observed. E. coli infection was dominated by 92.08%,
while other bacteria such as Enterococcus faecalis and
Enterococcus cloacae constituted a minute proportion of
UTIs.
Prevention of catheter-associated infection
Twenty years ago, the U.S. CDC clearly emphasized that
hand hygiene, sterile catheterization and closed drainage
systems were the necessary elements in preventing
CAUTI [43,44]. Recently, the Healthcare-Associated
Infections Allied Task Force proposed several frame-
works, including infection surveillance, enhancement of
education and training in the prevention of CAUTI, the
use of appropriate technology for catheter insertion,
replacement of indwelling urinary catheter by condoms
Figure 1 Control and JUC group at 16 hours A: Control group at 16 hours (CSLM 200X). B: JUC group at 16 hours (CSLM 200X)
Figure 2 Control and JUC group at 7 days A: Control group at 7 days (CSLM 200X). B: JUC group at 7 days (CSLM 200X).
He et al. Journal of Translational Medicine 2012, 10(Suppl 1):S14
http://www.translational-medicine.com/content/10/S1/S14
Page 5 of 8
and intermittent catheterization, immediate removal of
the catheter, and other frameworks to prevent the
occurrence of CAUTI [43,45,46].
The World Health Organization claimed systemic pro-
phylactic antibiotic, irrigation of bladder, instilling normal
saline or antibiotics, sterile drainage bag and other mea-
sures are ineffective in preventing the occurrence of
CAUTI [1]. The use of anti-microbial drugs, anti-microbial
drainage bag and irrigation of bladder can only temporarily
reduce the chance of bacteriuria [13]. Furthermore, some
studies have shown that the use of soap, skin cleansing
foam, povidone iodine or saline in perineal care do not
affect the incidence of CAUTI [47]. As for materials of the
catheter, the single biological surface coated with silicon,
polyurethane, synthetic biomaterials, or hydrogel material,
were not proven effective in the prevention of bacterial
colonization [5,16].
The formation of biofilm is regarded as one of the major
causes of anti-microbial resistance and refractory CAUTI
[13]. Therefore, the prevention of biofilm formation has
been the research focus toward reducing the incidence of
CAUTI. In this study, we investigated the use of new
nanotechnology anti-microbial spray JUC, composed of
organic silicon quaternary ammonium salt. JUC forms a
positively charged film which isolates and kills negatively
charged pathogenic micro-organisms including bacteria,
fungi and viruses. The physical attraction between the film
and the micro-organism would not lead to drug resistance
[30].
In the laboratory, the formation of biofilm can be
initiated by a small amount of bacteria. The bacteria
clump together and form bacterial colonies. It then starts
to form a biofilm. When the biofilm matures, it begins to
shrink and collapse [48,49]. In the in vitro study, the initial
stage of biofilm formation was observed at 16 hours of
bacterial culture in the control group. After 7 days of incu-
bation, aggregation of bacterial clumps was observed and
the surface of sample fragments was unevenly rough,
which illustrated the formation of mature biofilm. How-
ever, only few free bacteria, represented by red dots under
microscope, were also observed in the therapy group. A
thin membranous structure was observed which was at a
stage between the bacterial colony formation and the
initial formation of biofilm. The in vitro study clearly
demonstrated that the physical anti-microbial film formed
by JUC could prevent biofilm formation for 7 days upon
application, which was validated in the clinical study. A
significantly lower incidence of CAUTI was observed clini-
cally in the therapy group (4.52%) than in the control
group (13.04%), which further confirmed the effectiveness
of JUC in the prevention of CAUTI.
Comparison between clinical trials
The pre-operative use of anti-microbial drugs as an effec-
tive way for the prevention of bacterial infection is widely
accepted [50]. In many clinical trials, prophylactic anti-
biotics were commonly prescribed for the prevention of
infection in catheterized patients [5]. The UTI rate did
not exclude the factor of antibiotics use. In Tambyah’s
study [6], the mean antibiotics use was 1.6 ± 1.7 per
catheter-day, and the incidence of CAUTI was 14.9% in
the urology department. In the surgical unit, 1,162
patients were catheterized patients after surgery. The
onset of CAUTI was 6.4 ± 6.1 catheterized days, and the
incidence was 11.9% [6]. In Darouiche’s study [51], 124
patients were catheterized in place for 14 days with regu-
lar silicone bladder catheters or silicone bladder catheters
impregnated with minocycline and rifampin after radical
prostatectomy. All patients were given a single parental
dose of 1g cefazolin as prophylactic antibiotic before
anesthesia. The UTI rates measured 7 days after surgery
were 15.2% and 39.7% in patients with regular catheters
and medicated catheters respectively. The incidence was
much higher than the therapy or control group patients
of our study.
Compared to the study of 1,497 patients with an overall
incidence of CAUTI of 14.9% by Tambyah et al. [6], the
incidence of CAUTI was higher than the therapy group
(4.52%) and slightly higher than the control group
(13.04%) of our study. In Tambyah’s study, the patients
were catheterized with nitrofurazone-impregnated sili-
cone catheters, silver-polyurethane hydrogel catheters or
control catheters and obvious differences were not
observed in the incidence of UTI between medicated
catheters and control catheters. Despite the different
practices of the use of antibiotics between Tambyah’s
study and our study, it seems the duration and types of
post-operative antibiotics were not associated with the




















Therapy 575 0 26 (4.52%)* 24 1 0 0 0 1
Control 575 0 75 (13.04%) 69 2 2 1 0 1
* P<0.001, statistically significant
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incidence of CAUTI. However, a significantly reduced
incidence of CAUTI was observed in the therapy group
of our study, indicating that the use of JUC, which was
effective in preventing the biofilm formation, could be
vital to lowering the incidence of CAUTI.
Conclusions
In the clinical trial, only 4.52% of the patients from the
therapy group were diagnosed with CAUTI, compared
to 13.04% from the control group. In vitro testing also
showed no obvious biofilm formation in the therapy
group sprayed with JUC after 7 days of bacterial incuba-
tion. Biofilm began forming after 16 hours of incubation
in the control group. The results from the clinical trial
and in vitro test demonstrated the effectiveness of JUC
in the prevention of CAUTI and formation of biofilm.
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